For reference: liraglutide · 40 °C.
I have read the obvious sources and they disagree with each other, so I would rather ask people who have actually done this.
I have a working setup and a notebook, and I am prepared to be told that my setup is inadequate if that is the answer.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
Whatever the refrigerated figure is, divide it by about 11. 40 °C is 35 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 11 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. So a preparation with a twenty-eight day refrigerated figure has roughly 2 days at 40 °C on the same assumption — an order-of-magnitude answer, not a shelf life, and it says nothing about sterility, which has its own clock. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.
Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
| Pathway | Dominant when | Detected by |
|---|---|---|
| Deamidation | Solution, neutral to alkaline pH | RP-HPLC, +1 Da on MS |
| Oxidation | Light, trace metals, peroxides | RP-HPLC, +16 Da on MS |
| Hydrolysis | Solution, extremes of pH | RP-HPLC, fragment masses |
| Aggregation | Agitation, interfaces, high concentration | SEC, visual haze; often invisible on RP-HPLC |
| Freeze-concentration damage | Freeze-thaw of buffered solution | SEC, loss of recovered content |
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
At dilute concentrations, suspect adsorption before you suspect chemistry.
edited 6 Jun 2025 by sinead_gaffney — fixed an arithmetic slip in the third paragraph
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
Nothing here is medical advice, and research-use compounds are not approved for human use.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
edited 6 Jul 2025 by ten_mg_vial — added the placebo-arm figures
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.